ESSA Pharma
2 total number of assets per phase
0I
2II
0III
0APPROVED
This is a demo version of Gosset. Data is for educational purposes only; do not take financial or other decisions based on this data. Read full terms and conditions.
Assets
Drug | Indications male urogenital diseases, prostate cancer, genitourinary cancer | Phase Phase 2 | Study completion time 2022-09-30 |
Drug | Indications urogenital diseases, genital diseases, male urogenital diseases, prostate cancer, genitourinary cancer... | Phase Phase 2 | Study completion time 2017-12 |
Recent transactions
Type licensing | Buyer ESSA Pharma Inc. | Seller Janssen Research & Development, LLC | Deal size | Assets EPI-7386 | Date 2023-04-12 | Source |
Type investment | Buyer Coatue Management | Seller GV20 Therapeutics | Deal size | Assets | Date 2022-07-20 | Source |
Type investment | Buyer Pfizer | Seller Essa Pharma , Trillium Therapeutics , Vedanta Biosciences , Homology Medicines | Deal size $120.00M | Assets | Date 2021-01-13 | Source |
Estimated asset value over time
Timeline
ESSA Pharma Q1 2024 Update
2024-02-13
ESSA Pharma Inc. reports positive results from Phase 1 dose escalation study of masofaniten combined with enzalutamide in patients with mCRPC.
The company has a strong cash position to fund operations beyond 2025.
ESSA Pharma is advancing multiple combination studies and expects to report preliminary data in the second half of 2024.
ESSA Pharma Q1 2024 Update
2024-02-13
ESSA Pharma Inc. reports positive results from Phase 1 dose escalation study of masofaniten combined with enzalutamide in mCRPC patients.
The company has sufficient cash runway to fund operations beyond 2025.
ESSA Pharma is advancing multiple combination studies and expects to report preliminary data in the second half of 2024.
ESSA Pharma Presents Updated Data
2024-01-25
ESSA Pharma presented updated Phase 1 data on masofaniten (EPI-7386) in combination with enzalutamide at the 2024 ASCO Genitourinary Cancers Symposium.
The combination therapy showed deep and durable reductions in PSA levels in patients with metastatic castration-resistant prostate cancer (mCRPC).
The Phase 2 dose expansion study is currently underway, evaluating the combination therapy against single-agent enzalutamide.
ESSA Pharma Presents Updated Data
2024-01-25
ESSA Pharma presented updated Phase 1 data on masofaniten in combination with enzalutamide at the 2024 ASCO Genitourinary Cancers Symposium.
The combination therapy showed deep and durable reductions in PSA levels in patients with mCRPC and was well tolerated.
The Phase 2 dose expansion study is currently underway, evaluating the combination therapy against enzalutamide alone.
mCRPC Market Growth Forecast
2023-12-20
The metastatic castration-resistant prostate cancer (mCRPC) market is expected to grow at a CAGR of 7.5% from 2019 to 2032.
Several new drugs have been approved for mCRPC, including AKEEGA, TALZENNA, and LYNPARZA.
The mCRPC market is highly competitive with numerous approved treatments and a robust pipeline of emerging therapies.